Hoffmann-La Roche: Neoplasms trials
The registry lists 88 Neoplasms studies with Hoffmann-La Roche as lead sponsor. 2 are open to participants now and 25 have results posted.
Phase 1 55Phase 2 13Phase 3 12Phase 4 3No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)RecruitingNCT06884618Phase 1
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingNCT05862285Phase 3
- Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical PracticeTerminatedNCT05694013Phase 2/3Results posted
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 2Results posted
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04222972Phase 3Results posted
- A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT04177108Phase 3Results posted
- A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerCompletedNCT03194893Phase 3Results posted
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedNCT03037385Phase 1/2Results posted
- A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced CancerCompletedNCT02721641Phase 3Results posted
- Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic MelanomaCompletedNCT02663232Results posted
- A Study of Atezolizumab in Advanced Solid TumorsCompletedNCT02458638Phase 2Results posted
- A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT02457793Phase 1Results posted
- My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsCompletedNCT02091141Phase 2Results posted
- A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)CompletedNCT01804140Results posted
- A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic MelanomaCompletedNCT01765569Phase 1Results posted
- A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)CompletedNCT01765543Phase 1Results posted
- An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib ProtocolCompletedNCT01739764Phase 4Results posted
- An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored StudyCompletedNCT01588184Phase 4Results posted
- A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01562275Phase 1Results posted
- A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic FunctionCompletedNCT01546519Phase 1Results posted
- A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive CancersCompletedNCT01524978Phase 2Results posted
- A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 MutationCompletedNCT01286753Phase 2Results posted
- An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)CompletedNCT01168349Results posted
- Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid TumorsCompletedNCT00607048Phase 1Results posted
- A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.CompletedNCT00448136Phase 2Results posted
- A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00096993Phase 2Results posted
- Safety Study of rhuMAb 2C4 to Treat Advanced Solid TumorsCompletedNCT00027027Phase 1Results posted
- A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid TumorsWithdrawnNCT06372574Phase 1
- An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)Active, not recruitingNCT05112965Phase 3
- P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)TerminatedNCT04249947Phase 1
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3
- Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI TherapyCompletedNCT03333655Phase 4
- A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Active, not recruitingNCT03148418Phase 3
- A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02825940Phase 1
- A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid TumorsCompletedNCT02760797Phase 1
- Concordance Between ctDNA Assay and FoundationOneCompletedNCT02620527
- A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02558140Phase 1
- Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy SubjectsCompletedNCT02536391Phase 1
- Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic LeukemiaCompletedNCT02461316
- Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive MalignanciesCompletedNCT02441465Phase 1
- A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02410512Phase 1
- A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid TumorsTerminatedNCT02317419Phase 1
- A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02219724Phase 1
- A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.CompletedNCT02098967Phase 1
- A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid TumorsCompletedNCT02092792Phase 1
- The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT02031731Phase 1
- A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid TumorsCompletedNCT02004106Phase 1
- A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRASCompletedNCT01986166Phase 1
- Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer PatientsWithdrawnNCT01974258Phase 1
- A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid TumorsCompletedNCT01901172Phase 1
- A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic MalignancyCompletedNCT01851824Phase 1
- FoundationOne™ Test Registry StudyCompletedNCT01851213
- A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic MalignancyCompletedNCT01849666Phase 1
- A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic MalignanciesCompletedNCT01844674Phase 1
- A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment CharacteristicsCompletedNCT01775514
- A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer ParticipantsCompletedNCT01767623Phase 1
- A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic MelanomaWithdrawnNCT01765556Phase 1
- A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01688206Phase 1
- An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer StudiesCompletedNCT01677780Phase 1
- A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01633970Phase 1
- A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell OriginCompletedNCT01482377Phase 1
- A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except LeukemiaCompletedNCT01462175Phase 1
- A Study of RO5458640 in Patients With Advanced Solid TumorsCompletedNCT01383733Phase 1
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01375842Phase 1
- Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid TumorsCompletedNCT01362374Phase 1
- A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid TumorsCompletedNCT01358903Phase 1
- A Study of RO5045337 in Patients With Solid TumorsCompletedNCT01164033Phase 1
- A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid TumorsCompletedNCT01143753Phase 1
- A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid TumorsTerminatedNCT00985374Phase 1
- A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid TumorsCompletedNCT00909740Phase 1
- A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00854152Phase 1
- A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid TumorsCompletedNCT00817518Phase 1
- A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid TumorsTerminatedNCT00811993Phase 1
- A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.CompletedNCT00773526Phase 1
- A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.CompletedNCT00721266Phase 1
- Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) PatientsCompletedNCT00628043Phase 3
- A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.CompletedNCT00560144Phase 1
- A Study of RO5045337 [RG7112] in Patients With Advanced Solid TumorsCompletedNCT00559533Phase 1
- A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.CompletedNCT00532090Phase 1
- A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.CompletedNCT00493155Phase 1
- A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)CompletedNCT00480831Phase 2
- A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.CompletedNCT00400361Phase 1
- A Study of R547 in Patients With Advanced Solid Tumors.CompletedNCT00400296Phase 1
- A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following ChemotherapyCompletedNCT00109265Phase 2
- A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast CancerCompletedNCT00109239Phase 3
- A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerCompletedNCT00109226Phase 2
- An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer StudyCompletedNCT00109057Phase 2
- Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal CancerTerminatedNCT00047632Phase 3